Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns
Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns
Eosinophilia is common during natalizumab treatment for multiple sclerosis but risk factors are unknown. We aimed to identify demographic, clinical and laboratory characteristics predicting eosinophilia. Sustained eosinophilia occurred in 16.8%. Risk factors for sustained eosinophilia included baseline pre-treatment eosinophilia, medical conditions potentially associated with eosinophilia including allergies, and suboptimal compliance. One temporal profile was associated with the highest and most rapidly developing eosinophilia, and was less likely to resolve: in one such case, eosinophilia was symptomatic. Changes in eosinophil and lymphocyte counts were only weakly correlated, suggesting factors other than Very Late Antigen-4 (VLA-4) inhibition drive eosinophilia.
Eosinophilia, Integrin, Lymphocytosis, Monitoring, Multiple sclerosis, Natalizumab
Keshvari, Milad-Kazava
96867d15-3293-4aa2-a8e9-3c19dcc8d06e
van Someren, Frederick
7d0d6cd5-fe21-46e3-b479-cf7c38f748e0
Sheikh, Saima
82479e36-da61-45a9-b951-4f5f9b988f03
Galea, Ian
66209a2f-f7e6-4d63-afe4-e9299f156f0b
15 December 2021
Keshvari, Milad-Kazava
96867d15-3293-4aa2-a8e9-3c19dcc8d06e
van Someren, Frederick
7d0d6cd5-fe21-46e3-b479-cf7c38f748e0
Sheikh, Saima
82479e36-da61-45a9-b951-4f5f9b988f03
Galea, Ian
66209a2f-f7e6-4d63-afe4-e9299f156f0b
Keshvari, Milad-Kazava, van Someren, Frederick, Sheikh, Saima and Galea, Ian
(2021)
Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns.
Journal of Neuroimmunology, 361, [577729].
(doi:10.1016/j.jneuroim.2021.577729).
Abstract
Eosinophilia is common during natalizumab treatment for multiple sclerosis but risk factors are unknown. We aimed to identify demographic, clinical and laboratory characteristics predicting eosinophilia. Sustained eosinophilia occurred in 16.8%. Risk factors for sustained eosinophilia included baseline pre-treatment eosinophilia, medical conditions potentially associated with eosinophilia including allergies, and suboptimal compliance. One temporal profile was associated with the highest and most rapidly developing eosinophilia, and was less likely to resolve: in one such case, eosinophilia was symptomatic. Changes in eosinophil and lymphocyte counts were only weakly correlated, suggesting factors other than Very Late Antigen-4 (VLA-4) inhibition drive eosinophilia.
Text
Keshvari et al_accepted manuscript
- Accepted Manuscript
Text
1-s2.0-S0165572821002563-main
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Accepted/In Press date: 26 September 2021
e-pub ahead of print date: 29 September 2021
Published date: 15 December 2021
Additional Information:
Funding Information:
None.
Publisher Copyright:
© 2021 Elsevier B.V.
Keywords:
Eosinophilia, Integrin, Lymphocytosis, Monitoring, Multiple sclerosis, Natalizumab
Identifiers
Local EPrints ID: 452596
URI: http://eprints.soton.ac.uk/id/eprint/452596
ISSN: 0165-5728
PURE UUID: dc78773c-d175-4f00-a744-5bb06d3aacff
Catalogue record
Date deposited: 11 Dec 2021 11:28
Last modified: 17 Mar 2024 06:55
Export record
Altmetrics
Contributors
Author:
Milad-Kazava Keshvari
Author:
Frederick van Someren
Author:
Saima Sheikh
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
